Brand-name medications such as Zepbound, Mounjaro, Wegovy, and Ozempic may be prescribed when clinically appropriate and are FDA-approved for specific indications
In a phase III randomized controlled trial, 966 patients with mild-to-moderate MASH (stage F1b, F2 or F3) were randomly assigned to once-daily oral treatment with 80 mg or 100 mg resmetirom or placebo for 52 weeks 4
The following groups should avoid or exercise extreme caution: Pregnant or breastfeeding women Individuals with active cancers People with uncontrolled diabetes Those with severe cardiovascular conditions Individuals with pre-existing hormonal imbalances A medical consultation is MANDATORY before starting treatment, especially if you have any pre-existing conditions or concerns about your eligibility
Recent Findings Observational studies and continuous glucose monitoring (CGM) reports reveal a high prevalence of hypoglycemia in post-bariatric pregnancies, ranging from 50% to 58%
In adulthood, a direct relationship exists between serum E2 and GH secretion, which is stronger in women than in men
Participants with the highest body mass index (BMI) values (40 or above) were most likely to access semaglutide, which is not surprising given that this group has the highest risk for developing further metabolic diseasebut Podolsky says it reflects a trend that physicians may be restricting GLP-1 drugs to patients with the highest weight, and solely recommending lifestyle interventions to patients with BMI values of 35 or less
